Owen Mumford is delighted that our flagship sustainability initiative, ReSCiD (Remanufacturing for a Sustainable Future in Combination Injection Devices), has reached the final interview stage of the prestigious Innovate UK Sustainable Medicines Manufacturing Grand Challenge.
ReSCiD addresses a critical environmental challenge in the pharmaceutical industry: the widespread use of single-use combination injection devices. These devices, essential for delivering advanced therapies, contribute significantly to clinical waste and carbon emissions.
Our vision is to transition to a circular model where devices are returned, safely disassembled, cleaned, and remanufactured for reuse – a transformative shift for the industry.
This project brings together a powerful consortium of 18 partners, including world-class universities, pioneering SMEs, NHS collaborators and international experts. Together, we aim to:
Develop scalable remanufacturing processes
Build digital traceability systems
Engage with regulators to shape new standards
Demonstrate real-world feasibility through pilot trials
For over 70 years, Owen Mumford has been at the forefront of medical technology innovation and was among the first device companies globally to achieve B Corp certification. We strive to be a catalyst for positive change in our industry – leading by example, championing innovation, and shaping a healthier, more sustainable future for generations to come.
Our ReSCiD initiative has the potential to not only support the NHS’s Net Zero ambitions but also position the UK as a global leader in sustainable medical device innovation.
We look forward to the next stage of the process and thank Innovate UK for recognising the potential of this groundbreaking initiative.